Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 5/20 | 1.00 |
| ▸ | PDE4A | P27815 | 7/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daxalipram SCHEMBL450824 | 1.00 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CMAPK1 | |
| Daxalipram SCHEMBL7760245 | 1.00 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CMAPK1 | |
| SCHEMBL8489189 | 0.94 | PDE4B (0.89) | PDE4BPDE4DPDE4APDE4CMAPK1 | |
| SCHEMBL7760278 | 0.90 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4CMAPK1 | |
| SCHEMBL7764115 | 0.90 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4CMAPK1 | |
| SCHEMBL7763958 | 0.90 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4CMAPK1 | |
| SCHEMBL11435807 | 0.87 | PDE4B (0.77) | PDE4BPDE4DPDE4APDE4CKDM4E | |
| SCHEMBL7763217 | 0.86 | PDE4B (0.75) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL7764133 | 0.86 | PDE4B (0.75) | PDE4BPDE4DPDE4APDE4CMAPT | |
| SCHEMBL8486187 | 0.84 | PDE4B (0.72) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| EP-0859766-B1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AG (DE) | 2001-05-16 | — | — | EP | claimed |
| WO-2000076484-A1 | PHARMACEUTICAL PREPARATION WITH DELAYED RELEASE OF AN ACTIVE SUBSTANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-21 | — | — | WO | claimed |
| US-6025376-A | INHIBITORS OF TUMOR NECROSIS FACTOR, TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | claimed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-0859766-B1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AG (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000076484-A1 | PHARMACEUTICAL PREPARATION WITH DELAYED RELEASE OF AN ACTIVE SUBSTANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-21 | — | — | WO | disclosed |
| US-6025376-A | INHIBITORS OF TUMOR NECROSIS FACTOR, TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| EP-0859766-A1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997015561-A1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4B 3/4885PDE4D 10/4885PDE4A 1/4885 |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE4B 60/4885PDE4D 72/4885PDE4A 49/4885 |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | PDE4B 3156/4885PDE4D 3932/4885PDE4A 2567/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | PDE4B 3156/4885PDE4D 3932/4885PDE4A 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.